^
NEW:
Evidence
Click below to explore the latest additions to VERI
New
BRCA2 mutation
Fallopian Tube Cancer
BGB-290
Sensitive: A1 - Approval
BeiGene Press Release - 3 days
New
BRCA1 mutation
Ovarian Cancer
BGB-290
Sensitive: A1 - Approval
BeiGene Press Release - 3 days
New
BRCA2 mutation
Peritoneal Cancer
BGB-290
Sensitive: A1 - Approval
BeiGene Press Release - 3 days
New
BRCA1 mutation
Peritoneal Cancer
BGB-290
Sensitive: A1 - Approval
BeiGene Press Release - 3 days
New
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
European Pharmaceutical Review - 3 days
New
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
European Pharmaceutical Review - 3 days
New
BRCA2 mutation
Ovarian Cancer
BGB-290
Sensitive: A1 - Approval
BeiGene Press Release - 3 days
New
BRCA1 mutation
Fallopian Tube Cancer
BGB-290
Sensitive: A1 - Approval
BeiGene Press Release - 3 days
New
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
Roche Press Release - 5 days
New
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
FDA - 5 days
New
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
FDA - 5 days
New
No biomarker
Prostate Cancer
enzalutamide
Sensitive: A1 - Approval
European Medicines Agency - 6 days
New
No biomarker
NSCLC
durvalumab + CP-675206
Sensitive: B - Late Trials
AstraZeneca Press Release - 3 days
New
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: B - Late Trials
Merck (MSD) Press Release - 4 days
New
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive: B - Late Trials
Merck (MSD) Press Release - 4 days
New
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 5 days
New
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: B - Late Trials
Servier Press Release - 5 days
New
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 5 days
New
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: B - Late Trials
ESMO-BC 2021 - 1 week
New
HER-2 negative
HER2 Negative Breast Cancer
bevacizumab
Sensitive: B - Late Trials
ESMO-BC 2021 - 1 week
New
HER-2 positive
HER2 Positive Breast Cancer
neratinib
Sensitive: B - Late Trials
ESMO-BC 2021 - 1 week
New
HIF1A overexpression
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: B - Late Trials
ESMO-BC 2021 - 1 week
New
BACH1 overexpression
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: B - Late Trials
ESMO-BC 2021 - 1 week
New
MET N375S
Salivary Gland Cancer
crizotinib + pazopanib
Sensitive: C3 – Early Trials
Onco Targets Ther - 3 days
New
KDR C482R
Clear Cell Renal Cell Carcinoma
crizotinib + pazopanib
Sensitive: C3 – Early Trials
Onco Targets Ther - 3 days
New
BRCA2 mutation
Solid Tumor
Immunotherapy
Sensitive: C3 – Early Trials
JAMA - 3 days
New
ALK R1209Q
Colon Cancer
crizotinib + pazopanib
Sensitive: C3 – Early Trials
Onco Targets Ther - 3 days
New
EGFR mutation
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
Oncol Res Treat - 5 days
New
PD-L1 negative
Melanoma
pembrolizumab + ipilimumab
Sensitive: C3 – Early Trials
J Clin Oncol - 6 days
New
BRAF V600E + CDKN2A deletion + RB1 expression
Melanoma
vemurafenib + palbociclib
Sensitive: C3 – Early Trials
Clin Cancer Res - 6 days
New
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
BMC Cancer - 6 days
New
HER-2 positive
Gastric Cancer
RC48
Sensitive: C3 – Early Trials
Gastric Cancer - 6 days
New
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
J Clin Oncol - 6 days
New
HER-2 positive
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
Lancet Oncol - 6 days
New
HER-2 positive
Solid Tumor
RC48
Sensitive: C3 – Early Trials
Gastric Cancer - 6 days
New
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab + alpelisib + LJM-716
Sensitive: C3 – Early Trials
Clin Cancer Res - 6 days
New
BRAF V600K + CDKN2A deletion + RB1 expression
Melanoma
vemurafenib + palbociclib
Sensitive: C3 – Early Trials
Clin Cancer Res - 6 days
New
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
BRCA1 mutation
Breast Cancer
talazoparib
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
BRCA2 mutation
Breast Cancer
talazoparib
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
HR positive
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
ER positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
ER mutation
Estrogen Receptor Positive Breast Cancer
bevacizumab + paclitaxel
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
ER positive + PGR positive
HER2 Negative Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
ER positive
HER2 Negative Breast Cancer
letrozole
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
ER positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: C3 – Early Trials
ESMO-BC 2021 - 1 week
New
STRN-ALK fusion
NSCLC
crizotinib
Sensitive: C4 – Case Studies
Thorac Cancer - 3 days
New
STRN-ALK fusion
NSCLC
alectinib
Resistant: C4 – Case Studies
Thorac Cancer - 3 days
New
EGFR exon 19 deletion + T790M + C797S + HER-2 amplification
LUAD
afatinib + rivoceranib
Sensitive: C4 – Case Studies
Onco Targets Ther - 3 days
New
ARAF mutation + NRAS mutation
Melanoma
HM95573
Resistant: D – Preclinical
Nature - 5 days
New
MLPH overexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
HER-2 overexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
CXXC5 overexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
SFRP1 underexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
GPR160 overexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
GRB7 overexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
MYC underexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
CDH3 underexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
KRT5 underexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
KRT17 underexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
FOXA1 overexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
KRT14 underexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
New
MIA underexpression
Breast Cancer
ribociclib
Sensitive: D – Preclinical
ESMO-BC 2021 - 1 week
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our